Opioid antagonist effects of dezocine in opioid-dependent humans

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 2, 1996, Pages 206-217

  Strain, Eric C ^a,b   Preston, Kenzie L ^a   Liebson, Ira A ^a   Bigelow, George E ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEZOCINE; HYDROMORPHONE; METHADONE; NALOXONE; OPIATE ANTAGONIST; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DEPENDENCE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; OPIATE ADDICTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; VOLUNTEER;

ADULT; COGNITION; CYCLOPARAFFINS; HUMANS; HYDROMORPHONE; MALE; MONITORING, PHYSIOLOGIC; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; PSYCHOMOTOR PERFORMANCE; QUESTIONNAIRES;

EID: 0029910670     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90137-X     Document Type: Article

References (37)

1. Malis JL, Rosenthale ME, Gluckman MI. Animal pharmacology of Wy-16,225, a new analgesic agent. J Pharmacol Exp Ther 1975;194:488-98.
2. Staquet M. A double-blind study of dezocine in cancer pain. J Clin Pharmacol 1979;19:392-4.
3. Staquet M. Effect of parenteral dezocine and placebo in cancer pain. Curr Med Res Opin 1980;6:634-7.
4. Vinik HR, McFarland L, Wright D, Baker W. Double-blind post-operative study comparing multiple doses of dezocine (Wy 16225) with morphine and placebo [abstract]. Anesthesiology 1982;57:A189.
5. Galloway FM, Varma S. Double-blind comparison of intravenous doses of dezocine, butorphanol, and placebo for relief of postoperative pain. Anesth Analg 1986;65:283-7.
6. Stambaugh JE, McAdams J. Comparison of intramuscular dezocine with butorphanol and placebo in chronic pain: a method to evaluate analgesia after both single and repeated doses. Clin Pharmacol Ther 1987;42:210-9.
7. Downing JW, Brock-Utne JG, Barclay A, Schwegmann IL. Wy 16225 (dezocine), a new synthetic opiate agonist-antagonist and potent analgesic: comparison with morphine for relief of pain after lower abdominal surgery. Br J Anaesth 1981;53:59-63.
8. Gal TJ, DiFazio CA. Ventilatory and analgesic effects of dezocine in humans. Anesthesiology 1984;61:716-22.
9. Pandit UA, Kothary SP, Pandit SK. Intravenous dezocine for postoperative pain: a double-blind, placebocontrolled comparison with morphine. J Clin Pharmacol 1986;26:275-80.
10. Cohen RI, Edwards WT, Kezer EA, Ferrari DA, Liland AE, Smith ER. Serial intravenous doses of dezocine, morphine, and nalbuphine in the management of postoperative pain for outpatients. Anesth Analg 1993;77:533-9.
11. Lewis AJ, Kirchner T. A comparison of the cardiorespiratory effects of ciramadol, dezocine, morphine and pentazocine in the anesthetized dog. Arch Int Pharmacodyn 1981;250:73-83.
12. Romagnoli A, Keats AS. Ceiling respiratory depression by dezocine. Clin Pharmacol Ther 1984;35:367-73.
13. Rowlingson JC, Moscicki JC, DiFazio CA. Anesthetic potency of dezocine and its interaction with morphine in rats. Anesth Analg 1983;62:899-902.
14. Chen J, Smith ER, Cahill M, Cohen R, Fishman JB. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. Life Sci 1992; 52:389-96.
15. O'Brien JJ, Benfield P. Dezocine: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1989;38: 226-48.
16. Schaefer GJ, Holtzman SG. Morphine-like stimulus effects in the monkey: opioids with antagonist properties. Pharmacol Biochem Behav 1981;14:241-5.
17. Young AM, Stephens KR, Hein DW, Woods JH. Reinforcing and discriminative stimulus properties of mixed agonist-antagonist opioids. J Pharmacol Exp Ther 1984;229:118-26.
18. Young AM, Masaki MA, Geula C. Discriminative stimulus effects of morphine: effects of training dose on agonist and antagonist effects of mu opioids. J Pharmacol Exp Ther 1992;261:246-57.
19. Swain HH, Seevers MH. Evaluation of new compounds for morphine-like physical dependence in the rhesus monkey. Committee on Problems of Drug Dependence, National Academy of Sciences. Washington, DC: National Academy of Sciences Printing and Publishing Office, July 1974:1168-95.
20. Zacny JP, Lichtor JL, deWit H. Subjective, behavioral, and physiologic responses to intravenous dezocine in healthy volunteers. Anesth Analg 1992;74:523-30.
21. Jasinski DR, Preston KL. Assessment of dezocine for morphine-like subjective effects and miosis. Clin Pharmacol Ther 1985;38:544-8.
22. Beaver WT, Wallenstein SL, Houde RW, Rogers A. A clinical comparison of the effects of oral and intramuscular administration of analgesics: pentazocine and phenazocine. Clin Pharmacol Ther 1968;9:582-97.
23. DeNosaquo N. The hallucinatory effect of pentazocine (Talwin). JAMA 1969;210:502.
24. Oosterlinck W, Varbaeys A. Preliminary clinical experience with dezocine, a new potent analgesic. Curr Med Res Opin 1980;6:472-4.
25. Cohen RI, Edwards WT, Kezer EA, Ferrari DA, Liland AE, Smith ER. Serial intravenous doses of dezocine, morphine, and nalbuphine in the management of postoperative pain for outpatients. Anesth Analg 1993;77:533-9.
26. Preston KP, Bigelow GE, Liebson IA. Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. J Pharmacol Exp Ther 1988;246:441-8.
27. Preston KP, Bigelow GE, Liebson IA. Antagonist effects of nalbuphine in opioid-dependent human volunteers. J Pharmacol Exp Ther 1989;248:929-37.
28. Strain EC, Preston KP, Liebson IA, Bigelow GE. Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther 1992;261:985-93.
29. Strain EC, Preston KP, Liebson IA, Bigelow GE. Precipitated withdrawal by pentazocine in methadone-maintained volunteers. J Pharmacol Exp Ther 1993;267: 624-34.
30. Strain EC, Preston KP, Liebson IA, Bigelow GE. Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther 1995;272:628-38.
31. Fraser HF, Van Horn GD, Martin WR, Wolbach AB, Isbell H. Methods for evaluating addition liability: (A) "Attitude" of opiate addicts toward opiate-like drugs, (B) A short-term "direct" addiction test. J Pharmacol Exp Ther 1961;133:371-87.
32. Jasinski DR. Assessment of the abuse potential of morphine-like drugs (methods used in man). In: Martin WR, editor. Drug addiction, I. New York: Springer-Verlag, 1977:197-258.
33. Kolb L, Himmelsbach CK. Clinical studies of drug addiction; III: a critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Am J Psychiatry 1938;94:759-99.
34. McLeod D, Griffiths RR, Bigelow GE, Yingling J. An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 1982;14:463-6.
35. Cowan A, Lewis JW, MacFarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 1977;60:537-45.
36. Lizasoain I, Leza JC, Lorenzo P. Buprenorphine: bell-shaped dose-response curve for its antagonist effects. Gen Pharmacol 1991;22:297-300.
37. Cami J, Bigelow GE, Griffiths RR, Drummond DC. Clinical testing of drug abuse liability. Br J Addict 1991;86:1525-652.